Clinical Trials Directory

Trials / Completed

CompletedNCT00788372

An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain

A Long-Term Study of JNS020QD in Patients With Chronic Pain

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
142 (actual)
Sponsor
Janssen Pharmaceutical K.K. · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of fentanyl one-day transdermal patch (JNS020QD, patch containing a drug that is put on the skin so the drug will enter the body through the skin) in participants with chronic (lasting a long time) pain.

Detailed description

This is an open-label (all people know the identity of the intervention), multi-center (conducted in more than one center) and non-comparative study of fentanyl one-day transdermal patch. The study consists of 4 periods: Screening period (3-14 days), Treatment period 1 (4 weeks), Treatment period 2 (48 weeks), Tapering period (0-6 weeks) and Follow-up period (1 week). Treatment will be initiated at 12.5 microgram per hour (mcg/hr). In both Treatment period 1 and 2, the dose will be increased as per the Investigator's discretion, ranging from 12.5 mcg/hr to 100 mcg/hr and the maximum application dose will be 300 mcg/hr. However, in Treatment period 2, the dose will be increased on 7th day before the day of medical examination (only if the participant used rescue treatment for minimum of 3 times per day for minimum of 4 days). The patch will be applied on areas including the chest, abdomen, upper arm and femoral region and replaced daily. Efficacy will primarily be evaluated by visual analog scale (VAS) score. The total duration of the study treatment will be 52 weeks. Participants' safety will be monitored throughout the study.

Conditions

Interventions

TypeNameDescription
DRUGFentanylFentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.

Timeline

Start date
2008-11-01
Primary completion
2010-11-01
Completion
2010-11-01
First posted
2008-11-10
Last updated
2013-06-26
Results posted
2013-06-26

Locations

23 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT00788372. Inclusion in this directory is not an endorsement.